Generalized Pustular Psoriasis
📧 Sign up to get email alerts when something new happens for Generalized Pustular Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares [Phase 4]
This clinical trial update notes a Phase 4 study evaluating spesolimab for Generalized pustular psoriasis, with status active but not recrui…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Generalized Pustular Psoriasis Registry in Costa Rica
This ClinicalTrials.gov entry documents a Generalized Pustular Psoriasis registry sponsored by Caja Costarricense de Seguro Social in Costa …
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
This ClinicalTrials.gov registry study by CorEvitas is collecting real-world safety and effectiveness data on treatments for generalized pus…
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) [Phase 1]
A Phase 1 clinical study of TQH2929 Injection for generalized pustular psoriasis is currently active but not recruiting. The sponsor is list…
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP) [Phase 2]
A Phase 2 trial is evaluating the efficacy and safety of HB0034 in patients with generalized pustular psoriasis. The study is currently recr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-02-14Clinical Trial Update: Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis [Phase 2, Phase 3]
Phase 2/Phase 3 clinical trial evaluating long-term safety and efficacy of HB0034 in generalized pustular psoriasis is currently recruiting.